Experiences with tumour necrosis factor-α inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry

Rheumatology

Volumn 50, Issue 7, 2011, Pages 1337-1340

  Sevcic, Krisztina ^a   Orban, Ilonka ^a   Brodszky, Valentin ^b   Bazso, Anna ^a   Balogh, Zsolt ^a   Poor, Gyula ^a   Kiss, Emese ^a  

^a NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^b Operációkutatás és Aktuáriustudományok Tanszék docense   (Hungary)

Author keywords

Adalimumab; Anti tumour necrosis factor ; Biologic therapy registry; Etanercept; Inhibitors; JIA registry; Juvenile idiopathic arthritis; Therapy; Tumour necrosis factor

Indexed keywords

ADALIMUMAB; ETANERCEPT;

ADOLESCENT; ARTICLE; CHILD; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXILLA SINUSITIS; OTITIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKIN INFECTION; TREATMENT RESPONSE; UVEITIS;

ADOLESCENT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUNGARY; IMMUNOGLOBULIN G; MALE; PAIN MEASUREMENT; RANGE OF MOTION, ARTICULAR; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959486057     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker103     Document Type: Article

References (14)

1. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
2. Orban I, Ruperto N, Balogh Z. Paediatric Rheumatology International Trials Organisation. The Hungarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19(4 Suppl. 23):S81-5.
3. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
4. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med 1986;314:1269-76.
5. van Rossum MA, Fiselier TJ, Franssen MJ et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998;41:808-16.
6. Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. heumatology 2001;40:907-13.
7. Bowyer SL, Roettcher PA, Higgins GC et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol 2003;30: 394-400.
8. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
9. Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
10. Ruperto N, Lovell DJ, Cuttica R et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 007;56:3096-106.
11. Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
12. Prince FH, Twilt M, ten Cate R et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
13. Horneff G, De Bock F, Foeldvari I et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.
14. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann heum Dis 2008;67:1145-52.